XML 38 R29.htm IDEA: XBRL DOCUMENT

Operating Segments (Tables)

6 Months Ended

Jun. 30, 2025

Operating Segments [Abstract]

Schedule of Group’s CODM

The Group’s CODM is the Chief Executive Officer of the Company.

		Six months ended June 30, 2025
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	461			$	461
Total			-				461				461

Segment loss (gain)			2,543				170				2,713

Equity losses from the investment in MitoCareX											312
Finance expense (income), net											414
Loss on impairment of loans											5,973
Tax income											-

Loss											9,412

		Six months ended June 30, 2024
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	840			$	840
Total			-				840				840

Segment loss (gain)			3,040				487				3,527

Equity losses from the investment in MitoCareX											208
Finance expense (income), net											(51	)
Tax income											(5	)

Loss											3,679

		Year ended December 31, 2024
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	1,306			$	1,306
Total			-				1,306				1,306

Segment loss (gain)			4,873				2,443				7,316

Equity losses from the investment in MitoCareX											429
Finance expense (income), net											(259	)
Tax income											(14	)

Loss											7,472

		As of June 30, 2025
		Drug Development				Online Sales				Total

Segment Assets		$	3,497			$	1,642			$	5,139
Segment Liabilities		$	5,033			$	187			$	5,220

		As of December 31, 2024
		Drug Development				Online Sales				Total

Segment Assets		$	8,407			$	1,764			$	10,171
Segment Liabilities		$	1,194			$	226			$	1,420